Key result
Novel benzothiazepine and benzoxazepine derivatives demonstrate potent ACE inhibitory activity in vitro and in vivo.
Why the study?
New structural types of angiotensin converting enzyme inhibitors were designed and synthesized to explore their inhibitory activity.
Remains purely preclinical and should not change practice; leaves open the potential for novel ACE inhibitor classes.
The design and synthesis of new structural types of angiotensin converting enzyme (ACE) inhibitors, (R)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzothiazepine-5-acetic acids (7, 26, 33 and 37) and (S)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzoxazepine-5-acetic acids (8 and 27), are described. A number of compounds in these series showed potent ACE inhibitory activity in vitro and in vivo. The structure-activity relationship is also discussed.
No takes yet. Share an insight, caveat, or question.
Itoh et al. (1986) studied this question. 1,5-benzothiazepine and 1,5-benzoxazepine derivatives was evaluated on ACE inhibitory activity in vitro and in vivo. New 1,5-benzothiazepine and 1,5-benzoxazepine derivatives were synthesized and demonstrated potent angiotensin converting enzyme inhibitory activity in vitro and in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: